is a clinical-stage biotech company developing a new type of RNA-based medicines called Antibody Oligonucleotide Conjugates (AOCs). These medicines are designed to deliver genetic treatments directly ...

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced ...

Oligonucleotide Synthesis Market Size & Growth Analysis: According to a new report by SNS Insider, the global Oligonucleotide Synthesis Market was valued at USD 3.72 billion in 2023 and is projected ...

But when U.S. National Institute of Standards and Technology researchers Christina Bergonzo and Alexander Grishaev put ...

Getting therapeutic drugs past the blood-brain barrier has long been one of medicine's most difficult challenges, limiting ...

AMX0114 is an antisense oligonucleotide made to prevent or slow the degeneration of axons, which is a key driver of ALS ...

Researchers at Tokyo University of Science have developed Chol-HDOs, which efficiently penetrate the brain, overcoming ...

We have developed an enhanced ratiometric fluorosensor using carbon dots (CDs) functionalized with Probe (single stranded complementary oligonucleotide fragment) and ethidium bromide (EB), for ...

Getting therapeutic drugs past the blood-brain barrier has long been a major challenge in treating brain diseases. Now, researchers from Japan have explored how cholesterol-modified heteroduplex ...

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases ...

On the other hand, the oligonucleotide product segment is anticipated to expand at the highest rate during the forecast period. This growth is driven by the growing need for synthetic DNA and RNA ...